



- ✓ A systematic evaluation of standardized data sets can help to optimize framework conditions for TACE in future
- ✓ A variety of factors including specific post-interventional complications, the type of embolization method used as well as the hospital's annual case volume are associated with an increased in-hospital following TACE





Current trends and inhospital mortality of transarterial chemoembolization (TACE) in Germany between 2010 and 2019



- The minimally invasive procedure of TACE represents a standard oncologic procedure for the treatment of intermediate-stage hepatocellular carcinoma (HCC), cholangiocarcinoma (CCC), and liver metastases.
- Although a number of risk factors associated with post-interventional complications and increased mortality are described in the literature, comprehensive data on current trends and in-hospital mortality following TACE are largely lacking.

This study aims at providing a systematic overview on TACE indications and embolization methods and to identify factors associated with an increased inhospital mortality following TACE in order to further improve outcomes.

Methods

Based on standardized hospital discharge data provided by the German Federal Statistical Office, we systematically evaluate current clinical developments, postinterventional complications, and in-hospital mortality following TACE in Germany between 2010 and 2019.

Conclusions

- We identify a variety of factors such as post-interventional complications, the type of embolization method used as well as the hospital's annual case volume, which are associated with an increased in-hospital following TACE.
- These data might help to further reduce mortality of this routinely performed local-ablative procedure in future.

Acknowledgements

The authors acknowledge Janina Loske of the Federal Statistical Office of Germany for her professional support in the remote analysis of the data.

References

Llovet J M et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet. 2002; 359 1734-1739. Krieg S et al. Recent Trends and In-Hospital Mortality of Transarterial Chemoembolization (TACE) in Germany: A Systematic Analysis of Hospital Discharge Data between 2010 and 2019. Cancers (Basel). 2022 Apr 22

Contact information

PD Dr. med. Sven H. Loosen Clinic for Gastroenterology, Hepatology and Infectious Diseases University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf 40225 Düsseldorf, Germany

E-mail: Sven.Loosen@med.uni-duesseldorf.de Phone: +49 211 81 04488




S. KRIEG¹, T. ESSING^{1,2}, A. KRIEG³, C. RODERBURG¹, T. LUEDDE¹ and S. H. LOOSEN¹




- ¹ Dept. of Gastroenterology, Hepatology, Infectiology, University Hospital Düsseldorf, Germany
- ² Paracelsus Medical University, Hospital Nürnberg, Germany
- ³ Dept. of Surgery (A), University Hospital Düsseldorf, Germany


Results


. 49,595 individual cases undergoing TACE were identified in Germany between 2010 and 2019 (Fig. 1/2).






2. Overall in-hospital mortality was 1% and significantly higher in females compared to males (Fig. 3). In-hospital mortality significantly differed between the underlying indications for TACE (Fig. 4) as well as between different embolization agents (Fig. 5).







- 3. Post-interventional complications such as liver failure, sepsis, renal failure, and liver abscess were associated with a significantly increased in-hospital mortality (Fig. 6).
- 4. In-hospital mortality was significantly increased in centers with a low annual TACE case volume (Fig. 7).

Fig. 6: Impact of post-interventional complications following TACE on in-hospital mortality

